BURLINGAME, Calif.--(BUSINESS WIRE)--Neptune Medical, a leader in medical device innovation, today announced the successful spinout of its subsidiary, Jupiter Endovascular, following the completion of a $97 million Series D financing. Sonder Capital and Olympus Corporation of the Americas were significant participants in this round, along with investments from other existing and new investors..

。桑德资本（Sonder Capital）和美洲奥林巴斯公司（Olympus Corporation of the Americas）以及其他现有和新投资者的投资都是这一轮投资的重要参与者。

This financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as Chairman of the Board. It will also enable Jupiter Endovascular to focus on its novel endovascular technology platform..

这项融资将加强海王星医疗作为一家专注于胃肠道疾病的公司，扩展到胃肠道疾病的机器人领域，最近任命医疗机器人先驱弗雷德·摩尔博士为董事会主席就是证明。它还将使Jupiter Endovascular专注于其新颖的血管内技术平台。

'Neptune Medical is thrilled to announce the successful closure of our Series D financing and the spinout of Jupiter Endovascular. These significant milestones allow us to sharpen our focus on GI robotics while empowering Jupiter to drive innovation in endovascular treatments,' said Alex Tilson, Founder and CEO of Neptune Medical.

“海王星医疗公司（Neptune Medical）非常高兴地宣布，我们成功完成了D系列融资，并推出了Jupiter Endovascular。海王星医疗公司（Neptune Medical）创始人兼首席执行官亚历克斯·蒂尔森（Alex Tilson）说，这些重要的里程碑使我们能够更加专注于胃肠道机器人技术，同时使木星能够推动血管内治疗的创新。

'We are grateful to our investors for their unwavering support and confidence in our vision.'.

“我们感谢投资者对我们愿景的坚定支持和信心。”

Dr. Moll commented, 'The spinout of Jupiter Endovascular is a strategic move that aligns with our long-term goals. With dedicated resources and leadership, Jupiter is well-positioned to revolutionize endovascular therapies. Meanwhile, Neptune will continue to push the boundaries in GI robotics, delivering transformative solutions to patients and healthcare providers.

Moll博士评论道，“木星血管内扩张是一项符合我们长期目标的战略举措。凭借专注的资源和领导力，Jupiter处于彻底变革血管内治疗的有利地位。与此同时，海王星将继续推动胃肠道机器人技术的发展，为患者和医疗保健提供者提供变革性的解决方案。

We intend for both companies to lead the way in innovating within their respective specialties.'.

我们希望两家公司在各自的专业领域内引领创新。”

Chief Strategy Officer for Olympus, Gabriela Kaynor, added, 'We are excited to participate in this financing round for Neptune Medical. We believe Neptune's innovative approach to endoscopy has the potential to elevate the standard of care by improving patient outcomes.'

奥林巴斯首席战略官加布里埃尔·凯诺（GabrielaKaynor）补充说，“我们很高兴参加海王星医疗（Neptune Medical）的这轮融资。我们相信海王星创新的内窥镜检查方法有可能通过改善患者预后来提高护理标准。”

About Neptune Medical

关于Neptune Medical

Neptune Medical is at the forefront of developing advanced medical devices, with a primary focus on gastrointestinal robotics. The company's mission is to enhance patient outcomes through innovative technology and collaborative partnerships.

海王星医疗处于开发先进医疗设备的前沿，主要关注胃肠机器人。该公司的使命是通过创新技术和合作伙伴关系来提高患者的治疗效果。

About Jupiter Endovascular

关于木星血管内

Jupiter Endovascular, a spinout of Neptune Medical, is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions.

海王星医疗公司（Neptune Medical）推出的Jupiter Endovascular正在开发一类新的血管内手术，以实现直接手术进入导管干预的精确度和控制。

About Olympus Corporation

关于奥林巴斯公司

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states..

在奥林巴斯，我们致力于使人们的生活更健康、更安全、更充实。作为一家全球医疗技术公司，我们与医疗保健专业人员合作，为早期发现、诊断和微创治疗提供一流的解决方案和服务，旨在通过提高目标疾病状态的护理标准来改善患者预后。

For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.

100多年来，奥林巴斯一直追求通过生产旨在为全球客户提供最佳结果的产品来为社会做出贡献的目标。

For more information, visit www.olympus-global.com and follow our global X account: @Olympus_Corp.

有关更多信息，请访问www.olympus-global.com并访问我们的全球X帐户：@olympus\u Corp。

About Sonder Capital

关于Sonder Capital

Sonder’s extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D..

桑德的广泛有限合伙人网络是全球性的，包括行业领导者、高净值个人以及专注于投资改变游戏规则的医疗保健技术的领先家族理财办公室。Sonder Capital于2019年由医疗保健界名人JayWatkins和医学博士FredMoll共同创立。